ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2021 - 2026)

ARS Pharmaceuticals has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $397000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 41.79% year-over-year to $397000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 247.54% YoY) and the FY2025 annual result came in at $1.4 million, up 1630.38% from the prior year.
• Depreciation & Amortization (CF) slipped to $397000.0 in Q1 2026 per SPRY's latest filing, from $417000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $417000.0 in Q4 2025 and troughed at -$37000.0 in Q2 2022.
• A 5-year average of $140812.5 and a median of $64500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) sank 117.7% in 2022, then surged 2445.45% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $14000.0 in 2022, then jumped by 614.29% to $100000.0 in 2023, then tumbled by 71.0% to $29000.0 in 2024, then soared by 1337.93% to $417000.0 in 2025, then declined by 4.8% to $397000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $397000.0, $417000.0, and $391000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.